SCHEMBL3366165

SCHEMBL3366165

Fc1cc(Br)c(CBr)cc1F

nearest known ligand 0.45

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.34
KDM1A O60341 2/20 0.33
KCNH2 Q12809 2/20 0.33
KDM1B Q8NB78 1/20 0.33
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2528520 0.87 KDM1A (0.36) KDM1AKCNH2KDM1BALOX15ALOX12
SCHEMBL16860902 0.87 DPP4 (0.33) DPP4ALOX15ALOX12
SCHEMBL4826854 0.83 DPP4 (0.39) DPP4
SCHEMBL30149683 0.83 DPP4 (0.39) DPP4
SCHEMBL29545980 0.82 KDM1A (0.41) DPP4KDM1AKCNH2KDM1B
SCHEMBL377065 0.82 KDM1A (0.41) DPP4KDM1AKCNH2KDM1B
SCHEMBL22817440 0.81 KDM1A (0.39) DPP4KDM1AKDM1BALOX15ALOX12
SCHEMBL3363763 0.81 KDM1A (0.38) KDM1AKCNH2KDM1B
SCHEMBL3365678 0.81 GPR84 (0.35) KDM1AKDM1B
SCHEMBL2268703 0.80 ALOX15 (0.37) ALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115720578-B And tricyclic derivatives, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2025-06-13 CN disclosed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2024-07-16 US disclosed
CN-113286793-B Inhibitors of influenza virus replication of pyrrolopyrazines and pyridotriazines 共结晶制药公司 2024-04-05 CN disclosed
US-20240083888-A1 SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF REISTONE BIOPHARMA COMPANY LIMITED (CN) 2024-03-14 US disclosed
EP-4257588-A1 SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF Reistone Biopharma Company Limited (CN) 2023-10-11 EP disclosed
EP-4257588-A1 SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF Reistone Biopharma Company Limited (CN) 2023-10-11 EP disclosed
CN-116157405-A Cathepsin C small molecule inhibitor and medical application thereof 瑞石生物医药有限公司 2023-05-23 CN disclosed
CN-115720578-A Tricyclic derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-02-28 CN disclosed
EP-1490335-A2 BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2004-12-29 EP disclosed
US-20040254167-A1 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME CORP. 2004-12-16 US disclosed
WO-2004103276-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2004-12-02 WO disclosed
WO-2004069162-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2004-08-19 WO disclosed
WO-2004064778-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO. INC. (US) 2004-08-05 WO disclosed
WO-2004058266-A1 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2004-07-15 WO disclosed
WO-2004037169-A2 BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2004-05-06 WO disclosed
WO-2004032836-A2 ANTIDIABETIC BETA-AMINO HETEROCYLCIC DIPEPTIDYL PEPTIDASE INHIBITORS MERCK & CO., INC. (US) 2004-04-22 WO disclosed
WO-2004007468-A1 PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES MERCK & CO., INC. (US) 2004-01-22 WO disclosed
WO-2003082817-A2 BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254167-A1 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 DPP4 1/4885KDM1A 2762/4885KCNH2 2911/4885
US-20240083888-A1 SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF CTSF, CTSV, CTSB DPP4 442/4885KDM1A 3974/4885KCNH2 4479/4885
US-12037333-B2 Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication PLPBP, EIF2AK2, TYMP DPP4 415/4885KDM1A 1606/4885KCNH2 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.